Larger medtech companies have traditionally shied away from investing in the pediatric market, but the landscape is changing. In the last year alone, we witnessed the passage of the 21st Century Cures Act and the signing of the FDA Reauthorization Act (FDARA 2017) into law. The industry is ripe for innovation and these legislative advances present new opportunities to connect innovators with the investment community.